This week, the biotech firm AFFiRiS published the long awaited results of their Phase 1 clinical trial evaluating a vaccine for Parkinson’s.
The vaccine – called PD01A – targets a protein that clumps/aggregates together in certain neurons in the brains of people with Parkinson’s.
The multi-year study suggests that the treatment is safe and tolerated. In addition, it causes the immune system to generate antibodies that target the aggregated form of alpha synuclein.
And while it must be remembered that this is a small, open-label study, there are some intriguing statements made in the report.
In this article, there is a discussion on what PD01A is, a review of the results of the clinical study, and a summary of what happens next.
See the article from The Science Of Parkinson’s in full here.